GPRC5D-Targeted CAR T Cells for MyelomaSham Mailankody, Eric L. Smith, Hani Hassoun et al.|New England Journal of Medicine|2022Cited by 383
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignanciesTania Jain, Sham Mailankody, Andrea Knežević et al.|Blood Advances|2020Cited by 264
The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseasesEric L. Smith, Edward H. Schuchman|The FASEB Journal|2008Cited by 213
Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical TrialSham Mailankody, Eric L. Smith, Arnab Ghosh et al.|Blood|2018Cited by 100
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trialBenjamin Diamond, Ola Landgren, Neha Korde et al.|The Lancet Haematology|2021Cited by 95